» Articles » PMID: 14633861

Regulation of Apolipoprotein M Gene Expression by MODY3 Gene Hepatocyte Nuclear Factor-1alpha: Haploinsufficiency is Associated with Reduced Serum Apolipoprotein M Levels

Overview
Journal Diabetes
Specialty Endocrinology
Date 2003 Nov 25
PMID 14633861
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocyte nuclear factor-1a (HNF-1alpha) is a transcription factor that plays an important role in regulation of gene expression in pancreatic beta-cells, intestine, kidney, and liver. Heterozygous mutations in the HNF-1alpha gene are responsible for maturity-onset diabetes of the young (MODY3), which is characterized by pancreatic beta-cell-deficient insulin secretion. HNF-1alpha is a major transcriptional regulator of many genes expressed in the liver. However, no liver defect has been identified in individuals with HNF-1alpha mutations. In this study, we show that Hnf-1alpha is a potent transcriptional activator of the gene encoding apolipoprotein M (apoM), a lipoprotein that is associated with the HDL particle. Mutant Hnf-1alpha(-/-) mice completely lack expression of apoM in the liver and the kidney. Serum apoM levels in Hnf-1alpha(+/-) mice are reduced approximately 50% compared with wild-type animals and are absent in the HDL and HDLc fractions of Hnf-1alpha(-/-). We analyzed the apoM promoter and identified a conserved HNF-1 binding site. We show that Hnf-1alpha is a potent activator of the apoM promoter, that a specific mutation in the HNF-1 binding site abolished transcriptional activation of the apoM gene, and that Hnf-1alpha protein can bind to the Hnf-1 binding site of the apoM promoter in vitro. To investigate whether patients with mutations in HNF-1alpha mutations (MODY3) have reduced serum apoM levels, we measured apoM levels in the serum of nine HNF-1alpha/MODY3 patients, nine normal matched control subjects (HNF-1alpha(+/+)), and nine HNF-4alpha/MODY1 subjects. Serum levels of apoM were decreased in HNF-1alpha/MODY3 subjects when compared with control subjects (P < 0.02) as well as with HNF-4alpha/MODY1 subjects, indicating that HNF-1alpha haploinsufficiency rather than hyperglycemia is the primary cause of decreased serum apoM protein concentrations. This study demonstrates that HNF-1alpha is required for apoM expression in vivo and that heterozygous HNF-1alpha mutations lead to an HNF-1alpha-dependent impairment of apoM expression. ApoM levels may be a useful serum marker for the identification of MODY3 patients.

Citing Articles

Apolipoprotein M gene polymorphisms in childhood-onset type 1 diabetes in southern Brazil.

de Souza S, Lopes M, Martins B, da Costa M, Nesi-Franca S, Manica G Int J Biochem Mol Biol. 2023; 14(4):51-61.

PMID: 37736389 PMC: 10509533.


Biomarkers: Tools for Discriminating MODY from Other Diabetic Subtypes.

Firdous P, Nissar K, Masoodi S, Ganai B Indian J Endocrinol Metab. 2022; 26(3):223-231.

PMID: 36248040 PMC: 9555386. DOI: 10.4103/ijem.ijem_266_21.


Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes.

Baker N, Hammad S, Hunt K, Semler A, Klein R, Lopes-Virella M Diabetes. 2022; 71(8):1795-1799.

PMID: 35554520 PMC: 9490352. DOI: 10.2337/db21-0920.


HNF1A:From Monogenic Diabetes to Type 2 Diabetes and Gestational Diabetes Mellitus.

Li L, Jiang B, Sun L Front Endocrinol (Lausanne). 2022; 13:829565.

PMID: 35299962 PMC: 8921476. DOI: 10.3389/fendo.2022.829565.


The apoM/S1P Complex-A Mediator in Kidney Biology and Disease?.

Bisgaard L, Christoffersen C Front Med (Lausanne). 2021; 8:754490.

PMID: 34722589 PMC: 8553247. DOI: 10.3389/fmed.2021.754490.